review solid earn beat disappoint quarter
celltrion inc cti sales/op came higher
consensu solid beat manag confirm
account adjust owe transfer price time
driver partial product resumpt plant drive
profit opm vs initi remsima sc
product sale mix support blend margin
gener highest margin cse gpm
outlook lift op estim bn
bn given on-going plant ramp pencil
remsima sc mix expect larger volum
commit given annual mix guidanc
rais tp ep
given faster-than-expect earn recoveri howev
leav beyond earn unchang market
dynam volum uptak etc track within expect
solid earn beat celltrion inc cti earn
releas market close may sales/op came
bn higher consensu bbg
np came bn beat manag confirm
account adjust owe transfer price time
product resumpt remsima sc led earn
earn driver partial product resumpt plant
drive profit opm trough
recal plant product suspend due new
line instal oper initi remsima sc
product bn sale mix support blend margin
gener highest margin suspect gpm
remsima sc eye eu launch gpm seem
biosimilar eu truxima/eu herzuma view
figur celltrion inc parent entitygp contribut sale mix
figur remsima sc gpm estimateinf celltrion inc parent
estimate pot chg tp
number share mn
chg prev ep
larger volum commit manag annual
sale mix guidanc sellside-onli on-sit meet host
ceo manag guid confid mid-to-long term
manufactur capac cti secur outsourc site
ds drug substanc upstream dp drug product
downstream ad dp seem consider
remsima sc provid pre-filled syring
could enhanc patient access remsima sc clinic studi
us market track new biolog approv pathway
studi aim crohn disease/ulc coliti first
howev manag said may seek extrapol depend
discuss us fda result obtain origin
indic remicad indic without addit studi
await detail china biosimilar busi cti plan set
jv chines player addit earn support
chemic unit celltrion pharm
recoveri weak oper gpm vs
albeit profit contribut cti consolid op
rais tp ep
faster-than-expect earn recoveri leav
beyond earn unchang market dynam slow us volum
uptak eu price eros etc track within expect
believ us biosimilar market remain key culprit
read-though although fulli factor associ risk
model yet recent asp declin tp base mix dcf
mix price-to-earnings increas histor averag
averag
improv outlook vision provid ceo lift
op bn bn given on-going plant ramp
pencil remsima sc mix expect
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
ray certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori celltrion inc
signifi initi assumpt coverag
price rate histori pfe
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
charl martineau pm univers toronto rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
